Trial Profile
A double-blind placebo-controlled study of VP4896 for the treatment of mild-to-moderate Alzheimer's disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jun 2011
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Curaxis Pharmaceutical Corporation
- 16 Aug 2006 Status change
- 14 Dec 2005 New trial record.